Search Results - "Carter, Jonathan L."

Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies by Wingerchuk, Dean M., MD, MSc, FRCP(C), Carter, Jonathan L., MD

“…Abstract Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system disease that typically strikes young adults, especially women…”
Get full text

An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis by Valencia-Sanchez, Cristina, Carter, Jonathan L

“…In recent years there has been a dramatic rise in available disease-modifying therapies for the treatment of relapsing multiple sclerosis (MS). Dimethyl…”
Get more information

The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study by Solomon, Andrew J, Bourdette, Dennis N, Cross, Anne H, Applebee, Angela, Skidd, Philip M, Howard, Diantha B, Spain, Rebecca I, Cameron, Michelle H, Kim, Edward, Mass, Michele K, Yadav, Vijayshree, Whitham, Ruth H, Longbrake, Erin E, Naismith, Robert T, Wu, Gregory F, Parks, Becky J, Wingerchuk, Dean M, Rabin, Brian L, Toledano, Michel, Tobin, W Oliver, Kantarci, Orhun H, Carter, Jonathan L, Keegan, B Mark, Weinshenker, Brian G

“…OBJECTIVE:To characterize patients misdiagnosed with multiple sclerosis (MS). METHODS:Neurologists at 4 academic MS centers submitted data on patients…”
Get full text

Interleukin-6 inhibition with tocilizumab for relapsing MOG-IgG associated disorder (MOGAD): A case-series and review by Elsbernd, Paul M., Hoffman, William R., Carter, Jonathan L., Wingerchuk, Dean M.

“…•IL-6 plays a key role in MOGAD pathogenesis.•Tocilizumab is highly effective in preventing MOGAD relapses.•No reported MOGAD case treated with tocilizumab has…”
Get full text

Cerebral enhancement in MOG antibody-associated disease by Elsbernd, Paul, Cacciaguerra, Laura, Krecke, Karl N, Chen, John J, Gritsch, David, Lopez-Chiriboga, A Sebastian, Sechi, Elia, Redenbaugh, Vyanka, Morris, Padraig P, Carter, Jonathan L, Wingerchuk, Dean M, Tillema, Jan-Mendelt, Valencia-Sanchez, Cristina, Thakolwiboon, Smathorn, Pittock, Sean J, Flanagan, Eoin P

“…IntroductionLimited data exist on brain MRI enhancement in myelin-oligodendrocyte-glycoprotein (MOG) antibody-associated disease (MOGAD) and differences from…”
Get full text

The spectrum of acute cardiopulmonary events associated with multiple sclerosis exacerbations by Valencia-Sanchez, Cristina, Goodman, Brent P, Carter, Jonathan L, Wingerchuk, Dean M

“…Diverse acute neurological injuries may cause acute cardiopulmonary events including neurogenic pulmonary edema (NPE) and neurogenic stunned myocardium (NSM)…”
Get full text

Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review by Elsbernd, Paul M, Carter, Jonathan L

“…Monoclonal antibody therapies have secured an important role in the therapeutic landscape for the treatment of both relapsing and progressive forms of multiple…”
Get full text

JCV GCN in a natalizumab-treated MS patient is associated with mutations of the VP1 capsid gene by Agnihotri, Shruti P, Dang, Xin, Carter, Jonathan L, Fife, Terry D, Bord, Evelyn, Batson, Stephanie, Koralnik, Igor J

“…OBJECTIVE:To describe the clinical, neuroimaging, immunologic, and virologic characteristics of JC virus–associated granule cell neuronopathy (JCV GCN) in a…”
Get full text

Status of neurology medical school education: Results of 2005 and 2012 clerkship director survey by Carter, Jonathan L, Ali, Imran I, Isaacson, Richard S, Safdieh, Joseph E, Finney, Glen R, Sowell, Michael K, Sam, Maria C, Anderson, Heather S, Shin, Robert K, Kraakevik, Jeff A, Coleman, Mary, Drogan, Oksana

“…OBJECTIVE:To survey all US medical school clerkship directors (CDs) in neurology and to compare results from a similar survey in 2005. METHODS:A survey was…”
Get full text

Alliance for Clinical Education Perspective Paper: Recommendations for Redesigning the "Final Year" of Medical School by Reddy, Shalini T., Chao, Jason, Carter, Jonathan L., Drucker, Robert, Katz, Nadine T., Nesbit, Robert, Roman, Brenda, Wallenstein, Joshua, Beck, Gary L.

“…Background: Although medical school typically lasts 4 years, little attention has been devoted to the structure of the educational experience that takes place…”
Get full text

Positive neurologic phenomena with initiation of dalfampridine for multiple sclerosis by Thaera, Greg M, Wingerchuk, Dean M, Carter, Jonathan L

“…Abstract Objective Review cases of positive neurologic phenomena initiated or worsened with dalfampridine in patients with multiple sclerosis. Background Oral,…”
Get full text

Are Corticosteroids Efficacious for Preventing or Treating Neutralizing Antibodies in Multiple Sclerosis Patients Treated With Beta-Interferons?: A Critically Appraised Topic by Zarkou, Srijana, Carter, Jonathan L., Wellik, Kay E., Demaerschalk, Bart M., Wingerchuk, Dean M.

“…BACKGROUND:Persistent, high-titer neutralizing antibodies (NAbs) reduce or eliminate the biologic activity of interferon-beta (IFNB) therapies for multiple…”
Get full text

Do Cannabinoids Reduce Multiple Sclerosis-Related Spasticity? by Thaera, Greg M., Wellik, Kay E., Carter, Jonathan L., Demaerschalk, Bart M., Wingerchuk, Dean M.

“…BACKGROUND:The plant Cannabis sativa contains numerous cannabinoids, which are aromatic hydrocarbons that have central nervous system effects mediated through…”
Get full text

Health care reform legislation: Momentous implications for shaping pharmacy's future by Boyle, Cynthia J., Love, Raymond C., Tish Moczygemba, Leticia R., Carter, Jonathan L., Zeitler, Kristen

Get full text

Practical consultations: multiple sclerosis by Wingerchuk, Dean M, Carter, Jonathan L

“…People with multiple sclerosis (MS) are increasingly referred for specialty care to tertiary centers, particularly for advice regarding initiation and…”
Get more information

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies by Wingerchuk, Dean M, Carter, Jonathan L

“…Multiple sclerosis (MS) is a chronic inflammatory demyelinating central nervous system disease that typically strikes young adults, especially women. The…”
Get full text

Childhood-onset multiple sclerosis with progressive dementia and pathological cortical demyelination by Bunyan, Reem F, Popescu, Bogdan F Gh, Carter, Jonathan L, Caselli, Richard J, Parisi, Joseph E, Lucchinetti, Claudia F

“…To describe a case of childhood-onset progressive multiple sclerosis with dementia and evidence of extensive cortical demyelination from brain biopsy specimen…”
Get more information

Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders by Cohen, Jeffrey A, Carter, Jonathan L, Kinkel, R.Philip, Schwid, Steven R

“…There is increasing impetus to begin disease-modifying therapy for relapsing multiple (R-MS) early, before the development of irreversible tissue damage and…”
Get full text

Entrustable professional activities: A useful concept for neurology education by Horak, Holli, Englander, Robert, Barratt, Diana, Kraakevik, Jeff, Soni, Madhu, Tiryaki, Ezgi

“…Medical education is currently undergoing a paradigm shift from process-based to competency-based education, focused on measuring the desired competence of a…”
Get full text

Management of impairment, disability, and handicap due to multiple sclerosis by Stolp-Smith, K A, Carter, J L, Rohe, D E, Knowland, 3rd, D P

“…In this article, we update management measures for patients with multiple sclerosis (MS) that can improve or prevent impairment, disability, and handicap and…”
Get more information